ItalyThe article reports on Angelini Industries' financial results for 2025, highlighting a 4.6% increase in total revenue to €1.7 billion using the previous proportional consolidation method for the joint venture Fater. Angelini Pharma contributed €1.26 billion in revenue (+3.3% over 2024), representing three-quarters of the group’s total sales. The industrial technology division, through Angelini Technologies, recorded record revenues of over €390 million (+59% compared to 2024), accounting for 23% of the group’s overall revenue. Profit margins were positive, with EBITDA at €228.9 million, EBIT at €109.5 million, pre-tax profit at €168.9 million, and net profit at €127.4 million. The group employs around 5,600 people across 21 countries, with revenue generated primarily in Italy (37%), the rest of Europe (43%), and outside Europe (20%). CEO Sergio Marullo emphasized focusing capital, expertise, and managerial attention on activities that drive future development, particularly in high-innovation areas such as brain health, rare diseases, and industrial technology.
Bias read (Center): The article presents factual financial data about Angelini Industries without overt ideological framing. It focuses on corporate performance metrics, strategic decisions, and operational growth without taking a clear partisan stance. The tone remains objective, emphasizing business outcomes rather
